Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who …
DW Kim, DH Lee, JH Kang, K Park, JY Han, JS Lee… - 2014 - ascopubs.org
8011 Background: HM61713 is a novel, oral, selective inhibitor for EGFR mutations
including both activating mutations and T790M, but not EGFR wild-type. This phase 1 trial …
including both activating mutations and T790M, but not EGFR wild-type. This phase 1 trial …
[HTML][HTML] Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non–Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and …
Guidance concerning tyrosine kinase inhibitors (TKIs) for patients with wild type epidermal
growth factor receptor (EGFR) and advanced non–small-cell lung cancer (NSCLC) after first …
growth factor receptor (EGFR) and advanced non–small-cell lung cancer (NSCLC) after first …
[HTML][HTML] Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular cancer, 2018 - Springer
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations
PA Jänne - Seminars in oncology, 2005 - Elsevier
The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic
target for patients with non–small cell lung cancer (NSCLC). However, despite its almost …
target for patients with non–small cell lung cancer (NSCLC). However, despite its almost …
Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
M Wen, J Xia, Y Sun, X Wang, X Fu… - … : Targets and Therapy, 2018 - Taylor & Francis
Purpose Both epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and
chemotherapy are widely applied for the treatment of advanced non-small-cell lung cancer …
chemotherapy are widely applied for the treatment of advanced non-small-cell lung cancer …
The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
TE Stinchcombe - Current treatment options in oncology, 2016 - Springer
Opinion statement The objective response rate and progression-free survival observed with
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with …
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with …
Management of NSCLC disease progression after first-line EGFR tyrosine kinase inhibitors: what are the issues and potential therapies?
R Califano, O Romanidou, G Mountzios, L Landi… - Drugs, 2016 - Springer
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the
standard of care for advanced non-small cell lung cancer (NSCLC) patients whose tumor …
standard of care for advanced non-small cell lung cancer (NSCLC) patients whose tumor …
[HTML][HTML] Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene …
P Krawczyk, DM Kowalski, R Ramlau… - Oncology …, 2017 - spandidos-publications.com
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are routinely used
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …
to treat non-small cell lung cancer (NSCLC) in patients with common activating mutations of …
Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard
first-line option for non-small-cell lung cancer (NSCLC) harboring active EGFR mutations …
first-line option for non-small-cell lung cancer (NSCLC) harboring active EGFR mutations …
[HTML][HTML] Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer
N Xu, W Fang, L Mu, Y Tang, L Gao, S Ren, D Cao… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Current guidelines for lung cancer treatment with EGFR tyrosine kinase inhibitors (TKI)
include only patients with mutated EGFR, although some patients with wildtype EGFR (wt …
include only patients with mutated EGFR, although some patients with wildtype EGFR (wt …